Cerecor ’s Phase II clinical trial of CERC-301 to treat MDD fails to meet primary endpoint

US-based clinical-stage biopharmaceutical company Cerecor has reported that its Phase II clinical trial of CERC-301 to treat major depressive disorder (MDD) has failed to meet its primary endpoint.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news